CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT Qualitative Methodology in Cardiovascular Outcomes Research: A Contemporary Look When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Clinical Trial2017 Dec 20. [Epub ahead of print]

JOURNAL:J Interv Cardiol. Article Link

Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions

Ito R, Ueno K, Yoshida T et al. Keywords: calcified coronary lesions; drug-coated balloon

ABSTRACT


OBJECTIVES - To investigate the efficacy of drug-coated balloon (DCB) for calcified coronary lesions.


BACKGROUND - Calcified coronary lesions is associated with poor clinical outcomes after revascularization. Recently, DCB is emerging as an alternative strategy for de novo coronary lesions. However, reports describing the efficacy of DCB for calcified coronary lesions are limited.


METHODS - A total of 81 patients (96 lesions) who electively underwent DCB treatment for de novo coronarylesions were enrolled: 46 patients (55 lesions) in the calcified group and 35 patients (41 lesions) in the non-calcified group. Angiographic follow-up data and clinical outcomes after the procedure were evaluated.


RESULTS - The diameter of the DCB used was 2.5 ± 0.5 mm. No bail-out stenting was observed after DCB treatment. Rotational atherectomy was used in 82% of lesions in the calcified group. Follow-up angiography (median, 6.5 months after intervention) was performed for 59 patients (30 in the calcified group and 29 in the non-calcified group). Late lumen loss and rates of restenosis were comparable between the groups (0.03 mm in the calcified group vs -0.18 mm in the non-calcified group, P = 0.093 and 13.9% vs 3.03%, P = 0.095, respectively). The survival rates for target lesion revascularization free survival and major adverse cardiac events at 2 years were comparable between the groups (85.3% vs 93.4%, P = 0.64 and 81.4% vs 88.5%, P = 0.57, respectively).


CONCLUSION - Calcified coronary lesions might dilute the effect of DCB. However, clinical outcomes in the calcified group were similar to those in the non-calcified group.


© 2017, Wiley Periodicals, Inc.